glp-1 prescriptions q1 2025 Retention, Renewal, Results: Noom's GLP‑1 Companion Poll: 1 in 8 Adults

Study 4: Martens 2018, chronic NR supplementation Citation: Martens C.R., Denman B.A., Mazzo M.R., et al

Abstract This review summarizes the published as well as unpublished human studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p -synephrine, providing information and an assessment of the safety and efficacy of these widely used products

This marks a return to price as the primary barrier after side effects topped the list in 2025

It is important to note that, in the other large type 2 diabetes cardiovascular outcome trials, there were no statistically significant associations with the use of GLP-1/GIP agonists and negative eye outcomes